Abstract:The Wnt/β-catenin pathway is constitutively active and promotes multiple tumor processes, including breast cancer metastasis. However, the underlying mechanism by which the Wnt/β-catenin pathway is constitutively activated in breast cancer metastasis remains unclear. Inhibition of Wnt antagonists is important for Wnt/β-catenin signaling activation, and post-transcriptional regulation of these antagonists by microRNAs (miRNAs) might be a possible mechanism underlying signaling activation. Regulation of nuclear pre-mRNA domain-containing 1A (RPRD1A) is a known inhibitor of cell growth and Wnt/β-catenin signaling activity, but the function and regulatory mechanism of RPRD1A in breast cancer have not been clarified. The aim of this study was to understand how regulators of the Wnt/β-catenin pathway may play a role in the metastasis of this cancer. Methods: RPRD1A expression and its association with multiple clinicopathological characteristics was analyzed immunohistochemically in human breast cancer specimens. miR-454-3p expression was analyzed using real-time PCR. RPRD1A or miR-454-3p knockdown and overexpression were used to determine the underlying mechanism of their functions in breast cancer cells. Xenografted tumor model, 3D invasive culture, cell migration and invasion assays and sphere formation assay were used to determine the biofunction of RPRD1A and miR-454-3p in breast cancer. Electrophoretic mobility shift assay (EMSA), luciferase reporter assay, and RNA immunoprecipitation (RIP) were performed to study the regulation and underlying mechanisms of RPRD1A and miR-454-3p expression and their correlation with the Wnt/β-catenin pathway in breast cancer. Results: The Wnt/β-catenin signaling antagonist RPRD1A was downregulated and its upstream regulator miR-454-3p was amplified and overexpressed in metastatic breast cancer, and both were correlated with overall and relapse-free survival in breast cancer patients. The suppression by miR-454-3p on RPRD1A was found to activate Wnt/β-catenin signaling, thereby promoting metastasis. Simultaneously, three other negative regulators of the Wnt/β-catenin pathway, namely, AXIN2, dickkopf WNT signaling pathway inhibitor (DKK) 3 and secreted frizzled related protein (SFRP) 1, were also found to be targets of miR-454-3p and were involved in the signaling activation. miR-454-3p was found to be involved in early metastatic processes and to promote the stemness of breast cancer cells and early relapse under both in vitro and in vivo conditions. Conclusions: The findings indicate that miR-454-3p-mediated suppression of Wnt/β-catenin antagonist RPRD1A, as well as AXIN2, DKK3 and SFRP1, sustains the constitutive activation of Wnt/β-catenin signaling; thus, miR-454-3p and RPRD1A might be potential diagnostic and therapeutic targets for breast cancer metastasis.

BRD4 Promotes the Stemness of Gastric Cancer Cells Via Attenuating Mir-216A-3p-mediated Inhibition of Wnt/β-catenin Signaling.

Overexpression of BRD4 in gastric cancer and its clinical significance as a novel therapeutic target

BRD4 Promotes Glioma Cell Stemness Via Enhancing Mir‐142‐5p‐mediated Activation of Wnt/β‐catenin Signaling

BRD4 expression and its regulatory interaction with miR-26a-3p, DLG5-AS1, and JMJD1C-AS1 lncRNAs in gastric cancer progression

BRD4 Promotes Gastric Cancer Progression and Metastasis Through Acetylation-Dependent Stabilization of Snail

MiR-454-3p-Mediated Wnt/β-catenin Signaling Antagonists Suppression Promotes Breast Cancer Metastasis

BRD4 Promotes Tumor Growth and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.

miR-324-3p promotes gastric cancer development by activating Smad4-mediated Wnt/beta-catenin signaling pathway

Inhibition of BRD4 enhanced the tumor suppression effect of dasatinib in gastric cancer

LncRNA BACE1-AS Accelerates the Progression of Gastric Cancer Through Regulating as a ceRNA of miR-422a to Positively Control BRD4 Expression

BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.

Mir-23A/b Promote Tumor Growth and Suppress Apoptosis by Targeting PDCD4 in Gastric Cancer

Downregulation of BRD4 inhibits gallbladder cancer proliferation and metastasis and induces apoptosis via PI3K/AKT pathway

MicroRNA-4651 Targets Bromodomain-Containing Protein 4 to Inhibit Non-Small Cell Lung Cancer Cell Progression

BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression

Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail

Caveolin-2 is Regulated by BRD4 and Contributes to Cell Growth in Pancreatic Cancer

MiR-455-3p Inhibits Gastric Cancer Progression by Repressing Wnt/β-catenin Signaling Through Binding to ARMC8.

Mir-942 Promotes Cancer Stem Cell-Like Traits In Esophageal Squamous Cell Carcinoma Through Activation Of Wnt/Beta-Catenin Signalling Pathway

High level of BRD4 promotes non-small cell lung cancer progression

Bromodomain protein 4 is a novel predictor of survival for gastric carcinoma